Up to 73% of Atopic Dermatitis Patients Taking Lilly’s Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

Up to 73% of Atopic Dermatitis Patients Taking Lilly’s Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis New secondary analysis from Eli Lilly and Company’s (NYSE: LLY)…

Read MoreUp to 73% of Atopic Dermatitis Patients Taking Lilly’s Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel)in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate

Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel)in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate…

Read MoreBristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel)in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate

Public consultation of experts to join the Guideline Development Group (GDG) for Defeating Meningitis by 2030 Roadmap: Meningitis diagnosis, treatment and care guidelines

Public consultation of experts to join the Guideline Development Group (GDG) for Defeating Meningitis by 2030 Roadmap: Meningitis diagnosis, treatment and care guidelines Despite successful efforts to control meningitis in…

Read MorePublic consultation of experts to join the Guideline Development Group (GDG) for Defeating Meningitis by 2030 Roadmap: Meningitis diagnosis, treatment and care guidelines

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults Teva Pharmaceuticals, a U.S. affiliate…

Read MoreTeva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside…

Read MoreUpdate on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer

Update on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer

Update on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer The Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable…

Read MoreUpdate on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer

GSK’s respiratory syncytial virus older adult vaccine candidate gains positive European Medicines Agency CHMP opinion

GSK’s respiratory syncytial virus older adult vaccine candidate gains positive European Medicines Agency CHMP opinion GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency’s Committee for Medicinal Products…

Read MoreGSK’s respiratory syncytial virus older adult vaccine candidate gains positive European Medicines Agency CHMP opinion